Voyager Therapeutics, Inc., a biotechnology company dedicated to advancing neurogenetic medicines, announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. “Voyager has built a strong financial...

Acquisition adds premier fundraising, secondary solutions and direct investment capital capabilities to the firm’s market-leading private equity M&A and capital markets franchises

On Wednesday, June 5th, CCF Group successfully closed its first Additional Tier 1 (AT1) issuance following the acquisition of HSBC’s retail banking activities in France. The Group issued €225 million of AT1 further enhancing its very strong capital position. As a result, the Group’s proforma Total Capital Ratio now exceeds 20%. Concurrently, the Group launched a tender offer for the existing €100 million of AT1 instruments issued in 2019. Prior to announcing this operation on...

Security and reliability emerge as top priorities, with more than half of consumers saying they would leave their bank if they were involved in an AI-related scam

Managed accounts are helping employees of all ages with optimal benefit and uptake closer to retirement age The percentage of managed account members sharing personal data and goals has doubled in the last decade, enabling a more personalized experience to better meets their needs